ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $19 | $7.03 | -63% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $19 | $7.03 | -63% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $19 | $7.03 | -63% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $19 | $7.03 | -63% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $19 | $7.03 | -63% |
| D.E. Shaw | Q3 2025(8Q snapshot) | 3Q | $19 | $7.03 | -63% |
| Renaissance Technologies | Q1 2026(8Q snapshot) | 1Q | $7.17 | $7.03 | -2% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Arcturus Therapeutics Holdings Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 7, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193805-26-000578May 7, 2026
- Form 40001193805-25-001767Dec 19, 2025
- Form 40001193805-25-001766Dec 19, 2025
- Form 40001193805-25-001765Dec 19, 2025
- Form 40001193805-25-001764Dec 19, 2025
- Form 4/Aamend0001193805-25-001215Aug 20, 2025
- Form 40001193805-25-001212Aug 19, 2025
- Form 40001193805-25-000878Jun 11, 2025
- Form 40001193805-25-000877Jun 11, 2025
- Form 40001193805-25-000876Jun 11, 2025
- Form 40001193805-25-000875Jun 11, 2025
- Form 40001193805-25-000874Jun 11, 2025
- Form 40001193805-25-000873Jun 11, 2025
- Form 40001193805-25-000872Jun 11, 2025
- Form 40001193805-24-001493Dec 18, 2024
Fundamentals
XBRL · ARCTURUS THERAPEUTICS HOLDINGS INC.Annual figures sourced directly from ARCTURUS THERAPEUTICS HOLDINGS INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Arcturus Therapeutics Holdings Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 5, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 24, 2026
- 10-KAnnual reportMar 3, 2026
- 8-KMaterial eventMar 3, 2026
- S-3Registration (shelf)Dec 30, 2025
- 8-KMaterial eventDec 15, 2025
- 10-QQuarterly reportNov 12, 2025
- 8-KMaterial eventNov 10, 2025
- 8-KMaterial eventOct 22, 2025
- 8-KMaterial eventSep 26, 2025
- 8-KMaterial eventAug 29, 2025
- 10-QQuarterly reportAug 11, 2025
- 8-KMaterial eventAug 11, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $7.47 | $7.03 | -6% |
| AQR Capital Management | Q1 2026 | open | $7.40 | $7.03 | -5% |
| Point72 Asset Management | Q1 2026 | open | $7.40 | $7.03 | -5% |
| Renaissance Technologies | Q1 2026 | open | $7.17 | $7.03 | -2% |
| Millennium Management | Q4 2025 | open | $7.27 | $7.03 | -3% |
| D.E. Shaw | Q3 2025 | open | $19 | $7.03 | -63% |
| AQR Capital Management | Q2 2025 | Q4 2025 | $12 | $7.27 | -38% |
| Millennium Management | Q2 2025 | Q3 2025 | $12 | $19 | +65% |
| Point72 Asset Management | Q2 2025 | Q4 2025 | $12 | $7.27 | -38% |
| Citadel Advisors | Q3 2024 | Q1 2026 | $19 | $7.40 | -61% |
| Two Sigma Investments | Q3 2024 | open | $19 | $7.03 | -63% |
| AQR Capital Management | Q3 2024 | Q1 2025 | $19 | $18 | -6% |
| Millennium Management | Q3 2024 | Q1 2025 | $19 | $18 | -6% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $19 | $18 | -5% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.